Functional Assays for Neurodegeneration Drug Discovery Programs

Neurodegeneration programs increasingly require functional data from compartments and pathways that standard whole-cell assays cannot resolve. ION Biosciences supports lysosomal ion channel, transporter, GPCR, chloride cotransporter, and safety target programs, including proprietary HaloTag organelle-targeted dye delivery for lysosomal ion flux and pH measurement.

Scope a Neurodegeneration Assay Program View Neurodegeneration Target Coverage

Therapeutic Area Context

Neurodegeneration Programs Require Assays That Reach the Right Compartment

Lysosomal targets such as TMEM175 and TRPML1 raise a specific assay challenge: the relevant biology occurs inside the lysosomal lumen, while conventional fluorescence assays mainly report cytoplasmic signal. Transporters, dopaminergic and cholinergic GPCRs, KCC2, and safety targets add further complexity around ion selectivity, coupling pathway, substrate dependence, and off-target risk for CNS-active compounds.

ION addresses this with a platform designed for functional resolution across compartments and mechanisms. The proprietary HaloTag system routes fluorescent indicators and pH sensors into the lysosome for organelle-localized measurements. Whole-cell transporter, GPCR, chloride, sodium, calcium, and safety workflows can then be combined into panels that support Parkinson's disease, Alzheimer's disease, ALS, and related neurodegeneration programs.

CRO Services

Assay Services for Neurodegeneration Targets

ION structures neurodegeneration assay engagements around the compartment and mechanism that matter for the program. Whether the target is lysosomal, transporter-dependent, GPCR-coupled, or safety-flagged, the service table below reflects the full workflow from feasibility through pharmacology-ready data delivery.

Capability	What This Means for Your Program
Assay development	Build assays around the neurodegeneration mechanism, including lysosomal ion flux and pH, transporter activity, GPCR signaling, chloride cotransport, or excitability and safety targets.
Cell line generation	Generate stable or transient systems for transporters, GPCRs, and ion channels; for lysosomal biology, configure HaloTag targeting and dye localization workflows.
Assay optimization	Improve organelle-specific signal, colocalization, signal-to-background, Z', substrate or stimulus conditions, and compound compatibility for screening-ready performance.
Assay validation	Benchmark lysosomal targets, transporters, and GPCRs with reference activators, inhibitors, agonists, antagonists, and pathway controls appropriate to each mechanism.
Compound screening	Run primary screening, dose-response, hit confirmation, counter-screening, and selectivity profiling across lysosomal, transporter, GPCR, and safety panels.
Orthogonal validation	Automated patch clamp provides biophysical confirmation for ion channel hits; confocal colocalization imaging confirms lysosomal dye localization and HaloTag targeting fidelity. For priority compounds where fluorescence data raises mechanistic questions, orthogonal formats are available within the same engagement.
Pharmacology-ready data packages	Return quantitative curves, QC metrics, target-specific interpretation, and follow-up recommendations for lead triage and panel design.

Target Classes

Lysosomal Channels, Transporters, GPCRs, and Safety Targets Across Key Neurodegeneration Indications

ION supports mechanism-matched assay strategies across the major target classes relevant to neurodegeneration, from lysosomal ion channels and dopaminergic transporters to inhibitory pathway modulators and GPCR programs linked to Parkinson's disease, Alzheimer's disease, and ALS.

Lysosomal Ion Channels

Organelle-targeted functional assays for TMEM175 and TRPML1 using ION's proprietary HaloTag dye delivery platform. Lysosomal thallium flux, lysosomal pH, and calcium flux readouts enable direct pharmacological characterization of ion transport within the lysosomal lumen, in a 384-well screening-compatible format.

Monoamine and Excitatory Amino Acid Transporters

Functional assay development and inhibitor profiling for dopamine (DAT) and excitatory amino acid transporters (EAAT1, EAAT2, EAAT3). Sodium flux-based readouts support uptake inhibitor pharmacology and modulator profiling in recombinant stable cell systems with well-characterized pharmacological controls. Relevant to ALS, neuroprotection, and Parkinson's disease programs.

Dopaminergic and Adenosinergic GPCRs

cAMP, calcium, and engineered coupling strategies for D1, D2, D3, D5, and adenosine A2A receptor programs. Gs and Gi-coupled targets are supported with pathway-matched readouts and transient or stable cell system options, directly relevant to Parkinson's disease programs. Biased Gα15 coupling and Gi-GIRK thallium flux readouts available for mechanistic differentiation.

Muscarinic and Cholinergic GPCRs

Functional assay support for M1 and M4 receptors relevant to cognitive dysfunction and cholinergic pathway modulation in Alzheimer's disease and related indications. Gq and Gi coupling supported with calcium flux and cAMP readouts, including engineered Gα15 coupling strategies.

Chloride Cotransporters and Inhibitory Pathway Modulators

Chloride-selective readouts for KCC2 and related cotransporters using chloride flux and thallium flux-based assays. Relevant to GABAergic dysfunction and excitatory/inhibitory balance dysregulation in neurodegeneration and related CNS indications.

Neuroinflammatory Ion Channels

Functional assays for Kv1.3, a voltage-gated potassium channel highly expressed in microglia and infiltrating T cells, with established relevance to neuroinflammation in Parkinson's disease and Alzheimer's disease. Thallium flux-based readouts support inhibitor profiling and selectivity characterization in a 384-well format.

Validated Targets

Neurodegeneration Target Coverage

These are the targets ION can mobilize without a feasibility delay. Cell lines, HaloTag lysosomal configurations, and reference pharmacology are already established for the targets below. For targets not yet in the validated inventory, ION can assess feasibility and develop a screening-compatible workflow.

Target Area	In-House Targets	Readouts	Use Cases
Lysosomal potassium and proton channels	TMEM175, TRPML1	Lysomally-targeted thallium flux, pH, and calcium flux	Lysosomal potassium and proton transport pharmacology, activator and inhibitor profiling, Parkinson's disease target engagement
Excitatory amino acid transporters	EAAT1, EAAT2, EAAT3	Sodium flux, thallium flux, membrane potential	Uptake inhibitor pharmacology, modulator profiling, ALS and neuroprotection programs
Dopamine transporter	DAT	Sodium flux, substrate uptake assays	Inhibitor and releaser pharmacology, dopaminergic pathway modulation, Parkinson's disease programs
Chloride cotransporter	KCC2	Chloride flux, thallium-free potassium flux, thallium flux	GABAergic dysfunction, E/I balance modulation, PAM/NAM profiling
Dopaminergic and adenosinergic GPCRs	D1, D2, D3, D5, Adenosine A2A	cAMP, calcium flux, biased Gα15 coupling (calcium), Gi-GIRK thallium flux	Agonist, antagonist, PAM/NAM profiling; Gs and Gi-coupled screening; Parkinson's disease programs
Muscarinic GPCRs	M1, M4	cAMP, calcium flux, biased Gα15 coupling (calcium), Gi-GIRK thallium flux	Cholinergic pathway modulation, cognitive target profiling, Alzheimer's disease and PAM/NAM screening
Neuroinflammatory ion channels	Kv1.3	Thallium-free potassium flux, thallium flux, membrane potential	Microglial activation profiling, neuroinflammation target engagement, inhibitor and selectivity screening for Parkinson's disease and Alzheimer's disease programs

Don't see your target of interest? ION supports feasibility work for novel and emerging neurodegeneration targets.ION supports feasibility work for additional targets.

Why ION

Why Partner With ION for Your Neurodegeneration Discovery Campaign?

ION combines organelle-localized lysosomal assays with broader transporter, GPCR, chloride, and safety workflows. Neurodegeneration programs get pharmacologically interpretable data from the compartment or pathway that drives the biology, not a whole-cell surrogate that approximates it.

Organelle-Targeted HaloTag Dye Delivery

ION routes fluorescent ion indicators and pH sensors into the lysosomal lumen, enabling functional pharmacology for targets that whole-cell assays cannot resolve.

TMEM175 and TRPML1 Functional Workflows

Lysosomal thallium flux, lysosomal pH, and calcium flux assays support activator and inhibitor profiling for lysosomal channel programs.

Transporter Assays Without Radiotracers

Ion-selective fluorescent indicators can report transporter function in living cells for dopamine, glutamate, GABA, and related transporter programs.

Coupling-Matched GPCR Formats

cAMP, calcium, Gα15, and Gi-GIRK workflows support dopaminergic, adenosinergic, muscarinic, and other neurodegeneration-relevant GPCR targets.

Panel Thinking for CNS Programs

Primary target assays can be paired with hERG, NaV1.5, transporter, or receptor counter-screens to clarify selectivity and risk.

Mechanism-Forward Data Delivery

ION reports potency values, concentration-response curves, QC metrics, rank order, and counter-screen context alongside recommended next experiments. For lysosomal targets, data packages include colocalization confirmation and compartment-specific interpretation so the pharmacology is readable without requiring the sponsor team to reconstruct the assay context.

Featured Capability

Lysosomal Ion Channel Pharmacology With Organelle-Targeted Dye Delivery

Lysosomal ion channels such as TMEM175 are genetically linked to Parkinson's disease risk and play a direct role in maintaining lysosomal membrane potential and pH, both of which are required for normal autophagy and protein clearance. The assay challenge is compartment specificity: conventional fluorescence-based ion flux and pH readouts primarily report bulk cytoplasmic signals rather than lysosomal activity. For TMEM175 pharmacology, whole-cell assays can miss the biology that matters by measuring outside the relevant compartment.

Case Study

TMEM175 Lysosomal Thallium Flux and pH Assay Development in HEK293T Stable Cell Line

HEK293T TMEM175 stable cell line with lysosome-targeted HaloTag construct
Lysosomal thallium flux and lysosomal pH readouts in 384-well WaveFront Panoptic format
Colocalization imaging used to confirm lysosomal dye localization prior to screening
Pharmacological benchmarking with DCPIB and 4-AP as reference compounds

DCPIB 4-AP

Graph PlaceholderDose-response or assay validation data

Graph PlaceholderSupporting pharmacology or QC data

Frequently Asked Questions

Neurodegeneration Assay FAQs

What neurodegeneration targets can ION support?

ION supports neurodegeneration drug discovery programs across ion channels, transporters, GPCRs, and organelle-based targets involved in neuronal excitability, synaptic signaling, lysosomal function, protein clearance, neuroinflammation, and cellular homeostasis. Assays can be configured around the biology of the target, including lysosomal ion flux, transporter activity, GPCR signaling, membrane potential regulation, and pathway-selective pharmacology. This flexible platform approach allows ION to support programs across Parkinson's disease, Alzheimer's disease, ALS, Lewy body dementia, and related neurodegenerative indications without limiting assay development to a single target class or mechanism.

What is the HaloTag lysosomal dye delivery platform, and why does it matter?

Standard fluorescence-based ion flux and pH assays measure bulk cytoplasmic signal, not the signal originating from within the lysosomal lumen. For lysosomal ion channels like TMEM175 and TRPML1, this means conventional assay formats cannot distinguish lysosomal transport activity from background or off-target contributions. ION's HaloTag platform addresses this by fusing a HaloTag sequence to a lysosome-targeted signal, then using cell-permeable HaloTag ligand-dye conjugates to deliver fluorescent indicators specifically into the lysosomal compartment. Dye loading is restricted to the lysosome, confirmed by confocal colocalization imaging, and the resulting readout reflects ion flux or pH change within the organelle itself. This is a genuine differentiator: it is the only format that generates pharmacologically interpretable lysosomal ion channel data in a 384-well screening-compatible workflow.

Why is TMEM175 a high-priority neurodegeneration target?

TMEM175 encodes a lysosomal potassium channel that is required for maintaining lysosomal membrane potential and regulating lysosomal pH. Loss-of-function variants in TMEM175 are among the most replicated genetic risk factors for Parkinson's disease identified in large-scale GWAS studies. Mechanistically, TMEM175 dysfunction impairs lysosomal acidification and autophagy, leading to accumulation of alpha-synuclein and other aggregation-prone proteins implicated in neurodegeneration. Because TMEM175 activity directly affects both potassium conductance and proton transport, assays that measure lysosomal thallium flux and lysosomal pH simultaneously provide the most complete pharmacological picture of compound activity at this target.

How does ION measure transporter function without radiotracer assays?

ION measures transporter function using fluorescent ion indicators that report substrate-coupled ion movement in living cells. These assays can be configured around sodium, proton, chloride, thallium, or membrane potential-sensitive readouts depending on the transport mechanism of the target. The result is a scalable, kinetic assay format for transporter screening, inhibitor profiling, and dose-response characterization without requiring radiolabeled substrates, membrane vesicle preparations, or specialized radiotracer handling infrastructure.

How do ION's engineered GPCR assay platforms enable neurodegeneration research programs?

Gα15 and Gi-GIRK thallium flux assays are engineered GPCR platforms that convert receptor activation into robust functional signals for screening and pharmacology studies. Gα15 coupling routes GPCR activity into a calcium mobilization readout, while Gi-GIRK assays link Gi-coupled receptor activation to GIRK channel opening and thallium influx. These platforms support evaluation of agonists, antagonists, and modulators using scalable, mechanism-informed readouts. For neurodegeneration programs, they can help characterize GPCR targets involved in neuronal signaling, neuroinflammation, lysosomal regulation, and other disease-relevant pathways.

Can ION run a multi-target neurodegeneration panel in a single campaign?

Yes. ION's validated target inventory for neurodegeneration includes lysosomal ion channels, transporters, and GPCRs that can be profiled within a coordinated campaign. Assay formats are compatible across 384-well kinetic fluorescence readouts on the WaveFront Panoptic platform, enabling counter-screening, selectivity profiling, and rank-ordering across target classes in a common workflow. For lysosomal targets, the HaloTag dye delivery platform can be applied across multiple lysosomal ion channels. ION can propose a panel configuration, including appropriate counter-screens and pharmacological controls, based on the program's selectivity and decision-making requirements.

Ready to Build a Neurodegeneration Assay?

Bring ION the target, compartment or pathway hypothesis, expression system, compound format, and decision criteria. We can recommend a readout and validation plan for focused profiling or a multi-target campaign.

Talk to an Assay Scientist View All Therapeutic Areas